Engaging the Experts – A New Landscape: Biosimilars in Multiple Sclerosis
Topics: Multiple Sclerosis
106 Results
A New Landscape: Biosimilars in Autoimmune Indications
Topics: Rheumatology
Accelerating Biosimilar Adoption: Conversation with the Experts
Topics: Implementation
Checklists for workflow considerations relating to adalimumab biosimilars
Topics: Rheumatology
The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems
Topics: Economics, P&T Committee
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
Topics: Rheumatology
Health economics of disease-modifying therapy for multiple sclerosis in the United States
Topics: Multiple Sclerosis
Era of biosimilars in rheumatology: reshaping the healthcare environment
Topics: Rheumatology
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
Topics: Economics, Rheumatology
A place for biosimilars in the changing multiple sclerosis treatment
Topics: Multiple Sclerosis
Multiple Sclerosis Biosimilars Landscape
Topics: Multiple Sclerosis
Rheumatology Biosimilars Landscape
Topics: Rheumatology
New and upcoming biosimilar launches
Topics: Implementation
Humira™ biosimilar landscape overview
Topics: Rheumatology
Biosimilars and Biologics: Implementation and Monitoring in a Healthcare Setting
Topics: Implementation
Approved Risk Evaluation and Mitigation Strategies (REMS)
Topics: Implementation, Multiple Sclerosis
Prescribing Biosimilar and Interchangeable Biosimilar Products
Topics: Implementation
Curriculum Materials for Health Care Degree Programs – Biosimilars
Topics: Implementation
Overview of Biosimilar Products
Topics: Implementation
Biosimilars: What Patients Need to Know
Topics: Implementation
Page 1 of 6